Why the study?
Prior trials comparing multiple versus single arterial grafting in CABG, such as ART, had unexpected findings complicated by high crossover and non-study arterial graft use, leaving the superiority of multiple arterial grafting unconfirmed.
Does multiple arterial grafting (MAG) improve clinical outcomes compared to single arterial grafting (SAG) in patients undergoing coronary artery bypass surgery (CABG)?
Does multiple arterial grafting (MAG) improve clinical outcomes compared to single arterial grafting (SAG) in patients undergoing coronary artery bypass surgery (CABG)?
The ROMA trial is an ongoing large randomized trial designed to definitively test whether multiple arterial grafting provides superior clinical outcomes compared to single arterial grafting in CABG.
Answers are grounded in this paper and cite their sources.
ROMA completes enrollment in the largest RCT of MAG vs SAG; leaves open whether multiple arterial grafts improve CABG outcomes.
The Randomized Comparison of the Clinical Outcomes of Single versus Multiple Arterial Grafts (ROMA) trial (NCT03217006) [1] is the largest randomized trial testing the hypothesis that multiple arterial grafting (MAG) provides superior clinical outcomes compared to single arterial grafting (SAG) in patients undergoing coronary artery bypass surgery (CABG). Trial activities started in January 2017, the first patient was enrolled in January 2018, and the last one (# 4375) was enrolled on 14 April 2023. Here, we summarize the first 7 years of ROMA activities, with particular focus on those aspects that may potentially be relevant for trialists interested in designing or implementing other large cardiac surgery trials. As the trial is ongoing and the primary analysis has not been performed yet, no outcomes or individual patient data are provided. The stimulus to design a second large MAG trial came after evaluating the results of the 5-year analysis of the Arterial Revascularization Trial (ART) in 2016 [2]. Following almost 50 years of observational MAG versus SAG comparisons that in general favoured MAG [3] and in the presence of convincing evidence of better mid- and long-term patency rates of arterial versus venous grafts [4] ART was generally expected to confirm the superiority of MAG and to move the field towards its larger adoption [5]. The 5-year analysis of ART was surprising due to the almost perfect overlap of the survival and event-free survival curves of the 2 treatment arms [2]; in addition, the frequent utilization of the radial artery as an additional arterial graft in the SAG group, and the high crossover rate (that likely reflected the lack of confidence of the ART surgeons with the use of the bilateral internal thoracic artery), raised key concerns over whether ART could meaningfully test the MAG hypothesis when the final data were available. This was the key motivation to design a new MAG trial, building on the lessons learned from ART—the collaboration with the ART investigators at the early stage was very important to inform the design of ROMA (Table 1).
No takes yet. Share an insight, caveat, or question.
Gaudino et al. (2024) conducted an editorial in Coronary artery disease requiring coronary artery bypass surgery (n=4,375). Multiple arterial grafting (MAG) vs. Single arterial grafting (SAG) was evaluated on Major adverse cardiovascular events (all-cause mortality, stroke, non-procedural myocardial infarction, repeat revascularization).
Synapse has enriched 10 related papers. Consider them for comparative context: